IL-27-producing B cells in the antibody response

抗体反应中产生 IL-27 的 B 细胞

基本信息

  • 批准号:
    10211938
  • 负责人:
  • 金额:
    $ 44.32万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-02-02 至 2026-01-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY – IL-27-producing B cells in the antibody response Built on our novel findings that B cells can be induced to express high levels of IL-27 (IL27p28/EBI3 heterodimer), this proposal will explore molecular and cellular mechanisms underlying the role of IL-27 and IL-27-producing B cells (B-27 cells) in class-switched antibody (Ab) responses. As we contend, B-27 cells shape the magnitude and quality of T-dependent Ab responses, including those elicited by viral infections. As we also contend, they do so as “helper” B cells to enhance the function of their target “effector” B cells, i.e., those responding to antigens and differentiating into IgG-producing cells. Such class-switched Abs include IgG1, which directly neutralizes virus, and human IgG3 and mouse IgG2a/IgG2c (IgG2a), which have additional anti-viral effector functions. Owing to the unique requirement of both innate and adaptive immune receptor signals for their induction, B-27 cells are strategically positioned to mediate the potent effect of TLR ligands in boosting the Ab response. We hypothesize that B-27 cells are induced in a manner dependent on transcription factor BATF3, and optimize the Ab response by cooperating with IFNg to promote proliferation, survival and full differentiation of IgG-producing B cells. This is based on our compelling preliminary data indicating that: (i) as an important source of IL-27, B cells are induced to produce IL-27 after priming by TLR ligands and then stimulation by Tfh cell stimuli CD154 and IL-21; (ii) mice with B cell-specific deficiency in Il27p28, Ebi3 or Batf3 are impaired in IL-27 production and specific IgG2a responses; (iii) IL-27 activates STATs, directs CSR to IgG2a and promotes survival and plasma cell differentiation in B cells stimulated by CD154 and IL-21 in vitro; and (iv) IL-27 and IFNg together boost B cell growth and differentiation in vitro, and, conversely, combined IL-27R and IFNgR deficiency in B cells abrogates specific IgG2a responses and significantly impairs IgG1 responses in vivo. To test our hypothesis, we will (Aim 1) characterize B-27 cells induced in Tg(Il27p28-Gfp) reporter mice upon infection by vaccinia virus (VV), which is also used as a vector of a variety of vaccines, or immunization with conjugated hapten NP-CGG mixed with alum and TLR ligand LPS; and determine the cooperation of B-27 cells with IFNg in specific IgG responses and underlying effector B cell proliferation, survival, CSR/SHM, plasma cell and memory B cell differentiation. We will also (Aim 2) address the mechanisms underlying the role of BATF3 in Il27p28 induction by identifying its cis-elements in the Il27p28 locus and partner transcription factors in vitro; and analyze induction of B cell BATF3 and its impact on B-27 cell generation and Ab responses to VV infection and NP-CGG/alum/LPS in vivo. Finally, we will (Aim 3) analyze the cooperation of B-cell IL-27R and IFNgR signals in optimizing effector B cell growth and differentiation in response to VV infection in vivo and stimulation with CD154 and IL-21 in vitro; and address the underlying mechanisms, focusing on their synergy in regulating STAT signal outputs and gene expression. By unveiling the mechanisms and function of B-27 cells, our studies will have a sustained impact on the understanding of IgG responses to viral infections and vaccine development.
项目总结-抗体应答中产生IL-27的B细胞 基于我们的新发现,即B细胞可以被诱导表达高水平的IL-27(IL 27 p28/EBI 3异源二聚体), 该计划将探索IL-27和产生IL-27的B的分子和细胞机制 细胞(B-27细胞)的类别转换抗体(Ab)应答。正如我们所说,B-27细胞塑造了 和T依赖性抗体应答的质量,包括由病毒感染引起的应答。正如我们所主张的,他们 作为“辅助”B细胞来增强其靶“效应”B细胞的功能,即,那些对抗原有反应的 并分化成IgG产生细胞。此类类别转换的Ab包括IgG 1,其直接中和 病毒,以及人IgG 3和小鼠IgG 2a/IgG 2c(IgG 2a),其具有额外的抗病毒效应子功能。 由于先天性和适应性免疫受体信号对它们的诱导的独特要求,B-27 细胞的战略定位是介导TLR配体增强Ab反应的有效作用。 我们假设B-27细胞以依赖于转录因子BATF 3的方式被诱导, 通过与IFNg合作来优化Ab反应,以促进细胞的增殖、存活和完全分化, 产生IgG的B细胞。这是基于我们令人信服的初步数据表明:(一)作为一个重要的 IL-27的来源,B细胞在用TLR配体引发然后用Tfh刺激后被诱导产生IL-27 细胞刺激物CD 154和IL-21;(ii)在IL 27 p28、Ebi 3或Batf 3中具有B细胞特异性缺陷的小鼠, IL-27产生和特异性IgG 2a应答;(iii)IL-27激活STAT,将CSR引导至IgG 2a,并促进 体外由CD 154和IL-21刺激的B细胞中的存活和浆细胞分化;和(iv)IL-27和IFNg 在体外共同促进B细胞生长和分化,相反,联合IL-27 R和IFN γ R缺乏 在B细胞中,消除特异性IgG 2 a应答并显著损害体内IgG 1应答。 为了检验我们的假设,我们将(目的1)表征在Tg(IL 27 p28-GFP)报告小鼠中诱导的B-27细胞, 通过牛痘病毒(VV)感染,其也用作多种疫苗的载体,或用 结合半抗原NP-CGG与明矾和TLR配体LPS混合,并测定B-27细胞的协同作用 在特异性IgG应答和潜在效应B细胞增殖、存活、CSR/SHM、浆细胞 和记忆B细胞分化。我们还将(目标2)解决的机制,潜在的作用,BATF 3 通过体外鉴定Il 27 p28基因座中的顺式元件和伴侣转录因子来诱导Il 27 p28; 并分析B细胞BATF 3的诱导及其对B-27细胞生成和VV感染的Ab应答的影响 和NP-CGG/明矾/LPS体内。最后,我们将(目的3)分析B细胞IL-27 R和IFNgR的协同作用, 在响应体内VV感染和刺激而优化效应B细胞生长和分化中的信号 与CD 154和IL-21在体外;并解决潜在的机制,重点是它们在调节 STAT信号输出和基因表达。通过揭示B-27细胞的机制和功能, 将对理解IgG对病毒感染的反应和疫苗开发产生持续的影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Zhenming Xu其他文献

Zhenming Xu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Zhenming Xu', 18)}}的其他基金

IL-27-producing B cells in the antibody response
抗体反应中产生 IL-27 的 B 细胞
  • 批准号:
    10338194
  • 财政年份:
    2021
  • 资助金额:
    $ 44.32万
  • 项目类别:
IL-27-producing B cells in the antibody response
抗体反应中产生 IL-27 的 B 细胞
  • 批准号:
    10550179
  • 财政年份:
    2021
  • 资助金额:
    $ 44.32万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 44.32万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 44.32万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 44.32万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 44.32万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 44.32万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 44.32万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 44.32万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 44.32万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 44.32万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 44.32万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了